Editing Vertex Pharmaceuticals Incorporated (section)

=== 4D Molecular Therapeutics: ===
Valued at $755.2 million, revenue for FY 2022 $3.1 million and net income $107.5 million.

4D Molecular Therapeutics is an active biotechnology company that is dedicated to the development of gene therapy products aimed at curing genetic diseases. Leveraging its innovative Therapeutic Vector Evolution platform, the company has the capability to create adeno-associated virus (AAV) gene therapy vectors. These vectors play a crucial role in delivering therapeutic genes to diseased tissues or organs within the body. As a public company founded in 2013, 4D Molecular Therapeutics is committed to advancing the field of gene therapy and providing potential cures for a range of genetic disorders. With its focus on cutting-edge research and technology, the company aims to make significant strides in the treatment of genetic diseases, ultimately enhancing the lives of patients worldwide. Headquartered in Emeryville, CA, 4D Molecular Therapeutics continues to drive advancements in the biotechnology industry.